Evrolimus therapy for Rhabdomyoma

From Wagner R. et al. Echocardiography 2015. Online accessed September 2015. DOI:10.1111/echo.1 3015.

Newborn. Treated with Evrolimus (1 mg/m2 once daily). Resolution after 3 weeks of treatment. Trough level of Evrolimus was monitored. Lymphopenia and hypertriglyceridemia was noted when higher dose was used for the first 2 days.

Congenital heart defects and receipt of special education services

Tiffany Riehle-Colarusso et al.
Pediatrics 2015;136:496-503.

Compared with children without birth defects, children with CHD were 50% more likely to receive special education services (Adjusted Prevalence Rate Ratio 1.5)

Special education categories:
Intellectual disability (aPRR 3.8)
Sensory impairment (aPRR 3.0)
Other health impairment (aPRR 2.8)
Significant developmental delay (aPRR 1.9)
Specific learning disability (1.4)

Sildenafil - liquid preparation

Click on the image to enlarge

(10 mg/ml)

New therapy for high LDL - PCSK9 inhibitor

From an advertisement by AmGen in Cardiology News August 2015:

New therapy for high LDL level.

PCSK9 inhibitor

PCSK9 (Proprotein convertase subtilisin/kexin type 9) degrades LDL receptors in hepatocytes.

Injection Praluent (Alirocumab) 75 mg or 150 mg. self-administer, q2weeks, recently approved by FDA.

Hyperkalemia therapy - Patriomer

From Cardiology News Aug 2015

Patiromer - a pottasium binding polymer. Binds with K in GI tract and enables excretion in stool.

JAMA 2015:314:129-30.

New Heart Failure Medication - Sacubitril (Neprilysin inhibitor)

From Cardiology News Aug 2015:

RE: FDA approval for a combination medication (Sacubitril + Valsartan)

Sacubitril - a neprilysin inhibitor

Valsartaion - an angiotensin receptor blocker

Prenatal Detection Rate of CHD in US

From Pediatrics 2015;136(2):e378-e385.